Investor Presentaiton

SELECT TRIALS - RETEVMO Study Indication* Title Phase Patients Primary Outcome* ** Lilly Primary Completion Completion Medullary NCT04211337 Thyroid Cancer A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) 3 400 Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) May 2024 Nov 2026 NCT03157128 Non- Small Cell Lung Cancer A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) 1|2 875 Non- Small Cell NCT04194944 NCT04819100 Lung Cancer Carcinoma, Non- Small-Cell A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) 3 170 Lung * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Phase 1: MTD; Phase 2: ORR Mar 2024 Sep 2024 3 250 Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab) Dec 2024 Jul 2027 Event-Free Survival (EFS) Aug 2028 Nov 2032 Source: clinicaltrials.gov, July 13, 2023 47 2023 Q2 EARNINGS

View entire presentation